Thus, our results presented here possibly have broader implications beyond DYT-PRKRA. Luteolin may also be useful for treating diseases triggered by inflammation where involvement of PACT-PKR pathway has been established such as in hepatic stellate cells, which are major contributors for the progression of hepatic fibrosis (Nakamura et al., 2015). The gene discussed is PRKRA; the disease is Hepatic fibrosis.